Gemcitabine-induced acute coronary syndrome: A case report

Medical Principles and Practice

Volumn 18, Issue 1, 2008, Pages 76-80

  Ozturk, Banu ^a   Tacoy, Gulten ^a   Coskun, Ugur ^a   Yaman, Emel ^a   Sahin, Giray ^a   Buyukberber, Suleyman ^a   Yildiz, Ramazan ^a   Kaya, Ali O ^a   Topal, Salih ^a   Ozdemir, Murat ^a   Benekli, Mustafa ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Coronary syndrome; Gemcitabine; Left bundle branch block

Indexed keywords

DOCETAXEL; GEMCITABINE; IFOSFAMIDE;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; CORONARY ARTERY OBSTRUCTION; ELECTROCARDIOGRAM; FEMALE; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; ISCHEMIC HEART DISEASE; LUNG NODULE; PERCUTANEOUS CORONARY INTERVENTION;

ANTIMETABOLITES, ANTINEOPLASTIC; ASPIRIN; BUNDLE-BRANCH BLOCK; CORONARY ARTERY DISEASE; CORONARY VASOSPASM; DEOXYCYTIDINE; ELECTROCARDIOGRAPHY; FATAL OUTCOME; FEMALE; HUMANS; LEIOMYOSARCOMA; LUNG NEOPLASMS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 57349192822     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163051     Document Type: Article

References (12)

1. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-105.
2. Abbratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-1540.
3. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C: An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006;24:249-253.
4. Coskun U, Günel N, Yildirim Y: Gemcitabine induced pulmonary injury. Case Rep Pract Rev 2004;5:178-179.
5. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-3131.
6. Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302.
7. Labianca R, Beretta G, Clerici M, Frascini P, Luporini G: Cardiac toxicity of 5-fluorouracil: a study of 1083 patients. Tumori 1982;68:505-510.
8. Canale ML, Camerini A, Stroppa S, Porta RP, Caravelli P, Mariani M, Balbarini A, Ricci S: A case of acute myocardial infarction during 5-fluorouracil infusion. J Cardiovasc Med (Hagerstown) 2006;7:835-837.
9. Wijesingle N, Thompson PI, McAlister H: Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 2006;15:337-339.
10. Bdair FM, Graham SP, Smith PF, Javle MM: Gemcitabine and acute myocardial infarction: a case report. Angiology 2006;57:367-371.
11. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B: Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;113:772-778.
12. Kalapura T, Krishnamurthy M, Reddy CV: Acute myocardial infarction following gemcitabine therapy: a case report. Angiology 1999;50:1021-1025.